Below is an educational, technical answer to a question many patients and clinicians ask. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. Beyond needle-based approaches, focused laser energy delivered through endoscopic instruments can be used trans-urethrally to vaporize or coagulate bladder tumors and to treat benign prostatic hyperplasia (BPH) with the aim of limiting bleeding.
Is ablation as good as surgery for liver cancer?
For small hepatocellular carcinomas, published data suggest that thermal ablation and surgical resection can offer comparable local control in appropriately selected patients, but this is highly context dependent. Resection provides a tissue specimen for margin assessment and may be favored for certain tumor sizes or locations, while ablation is less invasive and can spare organ tissue. Factors such as tumor number, liver function, and surgical risk weigh heavily in the comparison. The relative merits are assessed individually within a multidisciplinary team rather than settled by a general statement.
What This Means in Practice
Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions. For lesions near large vessels, the heat-sink effect can influence the completeness of heat-based ablation and is factored into planning. Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
Frequently Asked Questions
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
Does ablation replace surgery?
Not necessarily; ablation is a local, minimally invasive option that may be considered instead of or alongside surgery in appropriately selected patients, and the decision is made within a multidisciplinary team.
About INVAMED
INVAMED is a medical device manufacturer headquartered in Ankara, Turkey, founded in 2005. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team. INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer. Achieving an adequate ablation margin around the tumor is a recognized goal in the literature, and the treating clinician judges whether a single or overlapping-ablation approach is warranted. Antenna gauge, active-tip length, and generator power (measured in watts) are the primary variables a clinician balances against the intended ablation zone size for a given lesion.
Related on INVAMED
- Oncology Ablation — product category
- MWA or RFA for hepatocellular carcinoma (HCC)? A Technical Comparison
- Peta Radiofrequency Ablation (RFA) System — Technical Overview
- What size tumor can be ablated (the 3 cm rule)?
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.